Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 14/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3262917 | 0.99 | HTR1A (0.48) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL9272212 | 0.93 | HTR1A (0.43) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9274910 | 0.92 | HTR1A (0.42) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL9527227 | 0.88 | APP (0.44) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9526976 | 0.87 | APP (0.43) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL8199122 | 0.87 | HTR1A (0.66) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL9273220 | 0.86 | HTR6 (0.40) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL9268546 | 0.82 | DRD2 (0.44) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL7645406 | 0.80 | DRD2 (0.57) | HTR1AHTR1DHTR1BDRD2SLC6A4 | |
| SCHEMBL3222849 | 0.79 | HTR1D (0.77) | HTR1AHTR1DHTR1BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5807571-A | Transdermal therapeutic systems for administering indole serotonin agonists | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1998-09-15 | — | — | US | claimed |
| EP-0671908-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-HT 1? RECEPTOR AGONISTS AND ABSORPTION ENHANCERS | GLAXO CANADA (CA) | 1998-05-06 | — | — | EP | claimed |
| EP-0639072-B1 | PHARMACEUTICAL COMPOSITIONS OF ALKYLSULPHONAMIDES 5HT1 AGONISTS FOR RECTAL ADMINISTRATION | GLAXO WELLCOME LAB (FR) | 1998-03-11 | — | — | EP | claimed |
| US-5705506-A | TREATMENT OF MIGRAINES OR HEADACHES | LABORATOIRES GLAXO SA (FR) | 1998-01-06 | — | — | US | claimed |
| US-5693654-A | Medicaments for treating intraocular pressure | GLAXO GROUP LIMITED (GB) | 1997-12-02 | — | — | US | claimed |
| EP-0671908-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-HT 1? RECEPTOR AGONISTS AND ABSORPTION ENHANCERS | GLAXO CANADA INC. (CA) | 1995-09-20 | — | — | EP | claimed |
| EP-0639072-A1 | PHARMACEUTICAL COMPOSITIONS OF ALKYLSULPHONAMIDES 5HT1 AGONISTS FOR RECTAL ADMINISTRATION | LABORATOIRE GLAXO WELLCOME (FR) | 1995-02-22 | — | — | EP | claimed |
| WO-1993024116-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-HT1 RECEPTOR AGONISTS AND ABSORPTION ENHANCERS | GLAXO CANADA INC. (CA) | 1993-12-09 | — | — | WO | claimed |
| WO-1993021916-A1 | PHARMACEUTICAL COMPOSITIONS OF ALKYLSULPHONAMIDES 5HT1 AGONISTS FOR RECTAL ADMINISTRATION | LABORATOIRES GLAXO SA (FR) | 1993-11-11 | — | — | WO | claimed |
| CN-1022243-C | Indole derivatives and process for preparation thereof | GLAXO GROUP LTD (GB) | 1993-09-29 | — | — | CN | claimed |
| EP-0303507-B1 | INDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 1993-07-28 | — | — | EP | claimed |
| US-4997841-A | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-03-05 | — | — | US | claimed |
| CN-1038807-A | The preparation method of indole derivatives | GLAXO GROUP LTD (GB) | 1990-01-17 | — | — | CN | claimed |
| EP-0303507-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | claimed |
| JP-1207288-A | — | — | None | — | — | JP | disclosed |
| US-9682037-B2 | Non-mucoadhesive film dosage forms | APR APPLIED PHARMA RESEARCH SA (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160022574-A1 | NON-MUCOADHESIVE FILM DOSAGE FORMS | LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH (DE) | 2016-01-28 | — | — | US | disclosed |
| CN-1038807-A | The preparation method of indole derivatives | GLAXO GROUP LTD (GB) | 1990-01-17 | — | — | CN | disclosed |
| JP-H01207288-A | INDOLE DERIVATIVE | GLAXO GROUP LTD | 1989-08-21 | — | — | JP | disclosed |
| EP-0303507-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022574-A1 | NON-MUCOADHESIVE FILM DOSAGE FORMS | SI, MUC1, FABP6 | HTR1A 291/4885HTR1D 1110/4885HTR1B 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.